BMO Capital Markets raised Ionis Pharmaceuticals (NASDAQ: IONS) to outperform from market perform on October 21, 2026, citing rapid adoption of Tryngolza. The upgrade included a price-target increase to $66 from $54, which BMO said implied roughly 45% upside from recent trading levels.
Key Takeaways
- BMO tied its upgrade to Tryngolza’s early commercial performance following its June 2026 launch.
- The firm projects peak Tryngolza revenue above $3 billion; that remains an analyst forecast.
Table of Contents
- Ionis upgrade centers on Tryngolza’s commercial potential
- Sales valuation contrasts with continuing losses
- Insider transactions
Ionis upgrade centers on Tryngolza’s commercial potential
Tryngolza, also known as olezarsen, was launched for severe hypertriglyceridemia in June 2026. BMO analyst David Lebowitz highlighted its fit for patients suffering acute pancreatitis and its potential to gain market share among high-risk populations.
The Carlsbad, California-based biotechnology company specializes in RNA-targeted medicines, primarily using antisense technology. Its revenue comes from partnerships, licensing, royalties and an expanding commercial business, including independently launched Tryngolza.
Sales valuation contrasts with continuing losses
Ionis’s price-to-sales ratio was 8.3, below its historical median of approximately 9.5 times. Trailing 12-month earnings per share were negative $3.47, and operating margins and cash flow were also negative.
Insider transactions
Insider transactions over the preceding 12 months showed approximately $1.1 million in purchases against $131.1 million in sales. Those figures establish net selling but do not, by themselves, explain the sellers’ motives.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
